FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Allergan Asks for Restasis ANDA Restrictions

[ Price : $8.95]

Allergan asks FDA to apply multiple restrictions to ANDAs citing its Restasis as the reference-listed drug.

OGD Seeing Record Year with ANDA Approvals

[ Price : $8.95]

With two months to go this fiscal year, CDERs Office of Generic Drugs moves toward eclipsing last years record approval (651 ANDAs...

Stimwave StimQ Nerve Stimulator Cleared by FDA

[ Price : $8.95]

FDA clears a Stimwave 510(k) for the StimQ Peripheral Nerve Stimulator System, a wireless, micro-technology neuromodulation device...

Mylan Blames FDA for Generic Drug Approval Delays

[ Price : $8.95]

Mylan CEO Heather Bresch blames FDA reorganization for delays in approvals for two new generic drugs.

Priority Review for Genentech sNDA for Zelboraf

[ Price : $8.95]

FDA accepts for priority review a Genentech supplemental NDA for Zelboraf (vemurafenib) for Erdheim-Chester disease (ECD) with BRA...

FDA Guide on CMC Postapproval Changes for BLAs

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance on CMC Postapproval Manufacturing Changes for Specified Biological P...

CGMP Consultant Recommended for Cellex-C

[ Price : $8.95]

FDA warns Canadas Cellex-C drug manufacturing firm about significant CGMP violations.

Multiple Violations Found at Philippines Skin Sciences

[ Price : $8.95]

FDA warns the Philippines Skin Sciences Laboratory about CGMP violations in its production of misbranded unapproved new drugs.

10 Inspection Observations in Biocon 483

[ Price : $8.95]

FDA releases the FDA-483 issued following an inspection at Indias Biocon sterile drug manufacturer.

Meeting Next Month on Assessing Benefits/Risks

[ Price : $8.95]

FDA announces a 9/18 public meeting to discuss topics related to the structured assessment of benefits and risks in drug regulator...